Skip to main content
SpringerLink
Log in

Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes

  • Original Article
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

Hepatitis C virus (HCV) genotype 3a is considered a significant risk factor for the development of liver diseases and hepatocellular carcinoma for most of the cases in Pakistan. Because of the limited efficiency of the current therapy, RNA interference (RNAi), which results in sequence-specific degradation of HCV RNA, has potential as a powerful alternative molecular therapeutic approach. The envelope genes (E1 and E2) of HCV come in immediate contact with cells during infection and therefore might be a relevant target for new drug development. In the present study, the expression of E1 and E2 genes of HCV genotype 3a was dramatically reduced at both the mRNA and protein level using gene-specific small interfering RNAs (siRNA) when compared to mock-transfected and cells treated with control siRNAs. The potential of siRNAs to inhibit HCV-3a replication in serum-infected Huh-7 cells was also demonstrated by combined treatment of siRNAs against the E1 and E2 genes, which resulted in a significant decrease in HCV viral copy number. This clearly demonstrates that the RNAi-mediated silencing of HCV E1 and E2 is among the first of its type for the development of an effective siRNA-based therapeutic option against HCV-3a.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

HCV:

Hepatitis C virus

DMEM:

Dulbecco’s modified eagle medium

HCC:

Hepatocellular carcinoma

PEG-IFN-α:

pegylated interferon α

RNAi:

RNA interference

siRNA:

small interfering RNA

References

  1. Parker SP, Khan HI, Cubitt WD (1999) Detection of antibodies to hepatitis C virus in dried blood spot samples from mothers and their offspring in Lahore, Pakistan. J Clin Microbiol 37:2061–2063

    PubMed  CAS  Google Scholar 

  2. Giannini C, Brechot C (2003) Hepatitis C virus biology. Cell Death Differ 10:S27–S38

    Article  PubMed  CAS  Google Scholar 

  3. Alter MJ (1997) Epidemiology of hepatitis C. Hepatology 3:62S–65S

    Article  Google Scholar 

  4. Hoofnagle JH (2002) Course and outcome of hepatitis C. Hepatology 36(5):S21–S29

    Article  PubMed  Google Scholar 

  5. Idrees M, Riazuddin S (2008) Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis 8:69

    Article  PubMed  Google Scholar 

  6. Ahmad W, Ijaz B, Javed FT, Jahan S, Shahid I, Khan FM, Hassan S (2010) HCV genotype distribution and possible transmission risks in Lahore, Pakistan. World J Gastroenterol 16:4321–4328

    Article  PubMed  Google Scholar 

  7. Idrees M, Rafique S, Rehman I, Akbar H, Yousaf MZ, Butt S, Awan Z, Manzoor S, Akram M, Aftab M, Khubaib B, Riazuddin S (2009) Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol 15:5080–5085

    Article  PubMed  CAS  Google Scholar 

  8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965

    Article  PubMed  CAS  Google Scholar 

  9. Dubuisson J, Rice CM (1996) Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin. J Virol 70:778–786

    PubMed  CAS  Google Scholar 

  10. Op De Beeck A, Voisset C, Bartosch B, Ciczora Y, Cocquerel L, Keck Z, Foung S, Cosset FL, Dubuisson J (2004) Characterization of functional hepatitis C virus envelope glycoproteins. J Virol 78:2994–3002

    Article  PubMed  CAS  Google Scholar 

  11. Bartosch B, Dubuisson J, Cosset FL (2003) Infectious hepatitis C virus pseudoparticles containing functional E1–E2 envelope protein complexes. J Exp Med 197:633–642

    Article  PubMed  CAS  Google Scholar 

  12. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796

    Article  PubMed  CAS  Google Scholar 

  13. Lavie M, Goffard A, Dubuisson J (2007) Assembly of a functional HCV glycoprotein heterodimer. Curr Issues Mol Biol 9:71–86

    PubMed  CAS  Google Scholar 

  14. Goffard A, Dubuisson J (2003) Glycosylation of hepatitis C virus envelope proteins. Biochemie 85:295–301

    Article  CAS  Google Scholar 

  15. Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA (2004) CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 78:1448–1455

    Article  PubMed  CAS  Google Scholar 

  16. Garry RF, Dash S (2003) Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins. Virology 307:255–265

    Article  PubMed  CAS  Google Scholar 

  17. Flint M, Logvinoff C, Rice CM, McKeating JA (2004) Characterization of infectious retroviral pseudotype particles bearing hepatitis- C virus glycoproteins. J Virol 78:6875–6882

    Article  PubMed  CAS  Google Scholar 

  18. Lavillette D, Pecheur EI, Donot P, Fresquet J, Molle J, Corbau R, Dreux M, Penin F, Cosset FL (2007) Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol 81:8752–8765

    Article  PubMed  CAS  Google Scholar 

  19. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S (1998) Binding of hepatitis C virus to CD81. Science 282:938–941

    Article  PubMed  CAS  Google Scholar 

  20. Meola A, Sbardellati A, Bruni EB, Cerretani M, Pezzanera M, Ceccacci A, Vitelli A, Levy S, Alfredo N, Traboni C, McKeating J, Scarselli E (2000) Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol 74:5933–5938

    Article  PubMed  CAS  Google Scholar 

  21. Cocquerel L, Kuo CC, Dubuisson J, Levy S (2003) CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol 77(19):10677–10683

    Article  PubMed  CAS  Google Scholar 

  22. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811

    Article  PubMed  CAS  Google Scholar 

  23. Zamore PD, Tuschl T, Sharp PA, Bartel DP (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101:25–33

    Article  PubMed  CAS  Google Scholar 

  24. Hammond SM, Bernstein E, Beach D, Hannon GJ (2000) An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404:293–296

    Article  PubMed  CAS  Google Scholar 

  25. Elbashir SM, Lendeckel W, Tuschl T (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15:188–200

    Article  PubMed  CAS  Google Scholar 

  26. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T (2001) Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 20:6877–6888

    Article  PubMed  CAS  Google Scholar 

  27. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498

    Article  PubMed  CAS  Google Scholar 

  28. Sharp PA (2001) RNA interference-2001. Genes Dev 15:485–490

    Article  PubMed  CAS  Google Scholar 

  29. Hannon GJ (2002) RNA interference. Nature 418:244–251

    Article  PubMed  CAS  Google Scholar 

  30. Cullen BR (2002) RNA interference: antiviral defense and genetic tool. Nat Immunol 3:597–599

    Article  PubMed  CAS  Google Scholar 

  31. Paddison PJ, Hannon GJ (2002) RNA interference: the new somatic cell genetics? Cancer Cell 2:17–23

    Article  PubMed  CAS  Google Scholar 

  32. Seo MY, Abrignani S, Houghton M, Han JH (2003) Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J Virol 77:810–812

    Article  PubMed  CAS  Google Scholar 

  33. Kapadia SB, Brideau-Andersen A, Chisari FV (2003) Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci 100:2014–2018

    Article  PubMed  CAS  Google Scholar 

  34. Wilson JA, Jayasena S, Khvorova A, Sabatinos S, Rodrigue-Gervais IG, Arya S, Sarangi F, Harris-Brandts M, Beaulieu S, Richardson CD (2003) RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci 100:2783–2788

    Article  PubMed  CAS  Google Scholar 

  35. Randall G, Grakoui A, Rice CM (2003) Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci 100:235–240

    Article  PubMed  CAS  Google Scholar 

  36. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Yi L, Kurosaki M, Taira K, Watanabe M, Mizusawa H (2003) Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 4:602–608

    Article  PubMed  CAS  Google Scholar 

  37. Kronke J, Kittler R, Buchholz F, Windisch MP, Pietschmann T, Bartenschlager R, Frese M (2004) Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J Virol 78:3436–3446

    Article  PubMed  Google Scholar 

  38. Prabhu R, Vittal P, Yin Q, Flemington E, Garry R, Robichaux WH, Dash S (2005) Small interfering RNA effectively inhibits protein expression and negative strand RNA synthesis from a full length hepatitis C virus clone. J Med Virol 76:511–519

    Article  PubMed  CAS  Google Scholar 

  39. Liu M, Ding H, Zhau P, Qin ZL, Gao J, Cao MM, Luan J, Wu WB, Qi ZT (2006) RNA interference effectively inhibits mRNA accumulation and protein expression of hepatitis C virus core and E2 genes in human cells. Biosci Biotechnol Biochem 70:2049–2055

    Article  PubMed  CAS  Google Scholar 

  40. Kanda T, Steele R, Ray R, Ray RB (2007) Small interfering RNA targeted to hepatitis C virus 5’ nontranslated regions exerts potent antiviral effect. J Virol 81:669–676

    Article  PubMed  CAS  Google Scholar 

  41. el-Awady MK, Tabll AA, el-Abd YS, Bahgat MM, Shoeb HA, Youssef SS, Bader el-Din NG, Redwan el RM, el-Demellawy M, Omran MH, el-Garf WT, Goueli SA (2006) HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J Gasteroentrol 12:4836–4842

    CAS  Google Scholar 

  42. Zekri AR, Bahnassy AA, El-Din HM, Salama HM (2009) Consensus siRNA for inhibition of HCV genotype-4 replication. Virol J 6:13

    Article  PubMed  Google Scholar 

  43. Kim M, Shin D, Kim SI, Park M (2006) Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. Virus Res 122:1–10

    Article  PubMed  CAS  Google Scholar 

  44. Kamegaya Y, Hiasa Y, Zukerberg L, Fowler N, Blackard JT, Lin W, Choe WH, Schmidt EV, Chung RT (2005) Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology 41:660–667

    Article  PubMed  Google Scholar 

  45. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J (2006) Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope glycans. J Biol Chem 282:25177–25183

    Article  Google Scholar 

  46. Goffard A, Callen N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, Dubuisson J (2005) Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 79:8400–8409

    Article  PubMed  CAS  Google Scholar 

  47. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM (2005) Complete replication of hepatitis C virus in cell culture. Science 309:623–626

    Article  PubMed  CAS  Google Scholar 

  48. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci 102:9294–9299

    Article  PubMed  CAS  Google Scholar 

  49. Guha C, Lee SW, Chowdhury NR, Chowdhury JR (2005) Part II: hepatitis C. Lab Anim 34:39–47

    Article  Google Scholar 

  50. Lazaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, Corey L, Coombs RW, Fausto N (2007) Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol 170:478–489

    Article  PubMed  CAS  Google Scholar 

  51. Buck M (2008) Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One 3:e2660

    Article  PubMed  Google Scholar 

  52. Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, Sacunha A, Larrey D, Dubuisson J, Coste J, McKeating J, Maurel P, Fournier-Wirth C (2008) Serum derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol 82:569–574

    Article  PubMed  CAS  Google Scholar 

  53. Wilson JA, Richardson CD (2005) Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5B coding region. J Virol 79:7050–7058

    Article  PubMed  CAS  Google Scholar 

  54. Watanabe T, Umehara T, Yasui F, Nakagawa S, Yano J, Ohgi T, Sonoke S, Satoh K, Inoue K, Yoshiba M, Kohara M (2007) Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome. J Hepatol 47:744–750

    Article  PubMed  CAS  Google Scholar 

  55. De Francesco R, Migliaccio G (2005) Challenges and successes in developing new therapies for hepatitis C virus. Nature 436:953–960

    Article  PubMed  Google Scholar 

  56. Korf M, Meyer A, Jarczak D, Beger C, Manns MP, Kruger M (2007) Inhibition of HCV subgenomic replicons by siRNAs derived from plasmids with opposing U6 and H1 promoters. J Virol Hepat 14:122–132

    Article  CAS  Google Scholar 

  57. Bian T, Zhou Y, Bi S, Tan W, Wang Y (2009) HCV envelope protein function is dependent on the peptides preceding the glycoproteins. Biochem Biophys Res Commun 378:118–122

    Article  PubMed  CAS  Google Scholar 

  58. Shin D, Lee H, Kim SI, Yoon Y, Kim M (2009) Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus. RNA 15:898–910

    Article  PubMed  CAS  Google Scholar 

  59. Morrica A, Giorgi M, Maggi F, Fornai C, Vatteroni ML, Marchi S, Ricchiuti A, Antonelli G, Pistello M, Bendinelli M (1999) Susceptibility of human and non-human cell lines to HCV infection as determined by the centrifugation-facilitated method. J Virol Methods 77:207–215

    Article  PubMed  CAS  Google Scholar 

  60. Ho YT, Wu SL, Lai IL, Cheng KS, Kao ST, Hsiang CY (2003) An in vitro system combined with an in-house quantitation assay for screening hepatitis C virus inhibitors. Antiviral Res 58:199–208

    Article  PubMed  CAS  Google Scholar 

  61. Pan Q, Henry SD, Metselaar HJ, Scholte B, Kwekkeboom J, Tilanus HW, Janssen HL, van der Laan LJ (2009) Combined antiviral activity of interferon-alpha and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing. J Mol Med 87:713–722

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Applied and Functional Genomics Laboratory, National Centre of Excellence in Molecular Biology, University of Punjab, Lahore, 53700, Pakistan

    Saba Khaliq, Shah Jahan, Bushra Ijaz, Waqar Ahmad, Sultan Asad & Sajida Hassan

Authors
  1. Saba Khaliq
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shah Jahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bushra Ijaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Waqar Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sultan Asad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sajida Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sajida Hassan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khaliq, S., Jahan, S., Ijaz, B. et al. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol 156, 433–442 (2011). https://doi.org/10.1007/s00705-010-0887-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-010-0887-6

Keywords

Search

Navigation